Bibliography
- HAUBRICH R, LALEZARI J, FOLLANSBEE SE et al.: Improved survival and reduced clinical progression in HIV-infected patients with advanced disease treated with saquinavir plus zalcitabine. Antiviral Ther. (1998) 3:33.
- ••Study demonstrating clinical benefit, supporting the use ofsaquinavir in HIV-infected patients.
- CAMERON DW, HEATH-CHIOZZI M, DANNER S et al: Randomised placebo-controlled trial of ritonavir in advanced 11IV-1 disease. Lancet (1998) 351:543–549.
- ••Study demonstrating clinical benefit, supporting the use ofritonavir in HIV-infected patients.
- HAMMER SM, SQUIRES KE, HUGHES MD et al. FOR THE AIDS CLINICAL TRIALS GROUP 320 STUDY TEAM: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4+ cell counts of 200 per cubic milliliter or less. N Engl. J. Med (1997) 337:725–733
- ••Study demonstrating a clinical benefit, supporting the use ofindinavir in HIV-infected patients.
- CARPENTER C, COOPER DA, FISCHL MA et al. FOR THE INTERNATIONAL AIDS SOCIETY-USA PANEL ON ANTIRETRO VIRAL THERAPY USE: Antiretroviral therapy in adults: updated recommendations of the Interna-tional AIDS Society-USA Panel. JAMA (2000) 283:381–390.
- ••Consensus report on antiretroviral therapy.
- NA VIA MA, FITZGERALD PMD, McKEVER BE et al: Three dimensional structure of aspartyl protease from human immunodeficiency virus. Nature (1989) 337:615.
- VELLA S: Rationale and experience with reverse transcriptase and protease inhibitors. J. Acquit-. Immune Defic. Syndr. Hum. Retrovirol (1995) (Suppl. 1):S58.
- KEMPF DJ, MARSH KC, DENISSEN JF et al.: ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA (1995) 92:2484.
- ROBERTS NA, MARTIN JA, KINCHINGTON D et al: Rational design of peptide-based HIV proteinase inhibitors. Science (1990) 248:358.
- WILLIAMS PEO, MUIRHEAD GJ, MADIGAN MJ et al.: Disposition and bioavailability of the HIV-proteinase inhibitor Ro 31-8959 after single doses in healthy volunteers. Br. J. Gun. Pharmacol. (1992) 32:155P.
- KITCHEN VS, SKINNER C, ARIYOSHI K et al: Safety and activity of saquinavir in HIV infection. Lancet (1995) 345:952.
- LALEZARI J, FOR THE NV15107 STUDY TEAM: Selecting the optimum dose for a new soft gelatin capsule formulation of saquinavir. J. AIDS. (1998) 19:195–197.
- SAAG MS, KILBY M, EHRENSING E et al.: Modulation of saquinavir steady-state pharmacokinetics with 'baby' doses of ritonavir in healthy volunteers. Abstracts of the 7th European Conference on Clinical Aspects and Treatment of HIV-Infection. Lisbon, Portugal (1999)829.
- VAN HEESWIJK RPG, VELDCAMP Al, MULDER JW et al.: The steady-state pharmacokinetics of saquinavir in a once daily dosing regimen with a low dose of ritonavir. Abstracts of the 7th European Conference on Clinical Aspects and Treatment of HIV-Infection. Lisbon, Portugal. (1999):830.
- DEUTSCH P, TEPPLER H, SQUIRES K et al.: Antiviral activity of L-735-524, an HIV protease inhibitor, in infected patients. Abstracts of the 34th Intel-science Confer-ence on Antimicrobial Agents and Chemotherapy. Orlando, USA (1994):159.
- MELLORS J, STEIGBIGEL R, GULICK R et al :Antiretroviral activity of the oral protease inhibitor, MK-639, in p24 antigenemic, HIV-1 infected patients with 500 CD4/mm3. Abstracts of the 35th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA. (1995) :1172.
- QUART B, CHAPMAN S, PETERKIN J et al.: Phase I safety, tolerance, pharmacokinetics and food effects studies of AG1343 - a novel HIV protease inhibitor. Program and abstracts of the 2nd National Conference on Human Retroviruses. Washington, USA. (1995):LB3.
- SCHOOLEY RT, FOR THE 141W94 INTERNATIONAL STUDY GROUP: Preliminary data on the safety and antiviral efficacy of the novel protease inhibitor 141W94 in HIV-infected patientsa with 150–400 CD4+ cells/mm3. Abstracts of the 35th International Conference on Antimicrobial Agents and Chemotherapy. New Orleans, USA. (1996):LBO7a.
- CARR A, SAMARAS K, BURTON S et al.: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 12:F51–58.
- CLUMECK N, COLEBUNDERS B, VANDERCAM B et al. and the PICASSO TRIAL GROUP: Randomized comparative outcome trial of indinavir (0 and ritonavir (R) in protease inhibitor (P1) naive patients (p) with CD4+ below 100 cells/ul. Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. Chicago, USA. (1998):MP386.
- STUART JWTC, SCHURMAN R, BURGER DM et al.: Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE). AIDS (1999) 13(7):F53–F58.
- MONTANER JSG, MELLORS JW: Better salvage therapy for 11IV-1 infection still needed. Lancet (1999) 353:1857.
- STASZEWSKI S, MORALES-RAMIREZ J, TASHIMA KT et al.: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of 11IV-1 infection in adults. N Engl. J. Med. (1999) 341 (25) :1865–1873.
- CAMERON WD, JAPOUR AJ, XU Y et al.: Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS (1998) 13:213–224.
- KIRK 0, KATZENSTEIN TL, GERSTOFT J et al.: Combina-tion therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a random-ized trial. AIDS (1999) 13:F9–16.
- DEEKS SG, GRANT RM, BEATTY GW et al.: Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir and ritonavir failure. AIDS (1998) 12:F97–102.
- KAUFMANN GR, DUNCOMBE C, CUNNINGHAM P et al. Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of 11W-1 infected individuals. AIDS (1998) 12: 1625-1630.
- KUMAR GN, DYKSTR J, ROBERTS EM et al.:Potent inhibi-tion of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interac-tion. Drug Metab. Dispos. (1999) 27(8)902–908.
- CARILLO A, STEWART KD, SHAM HL et al.: In vitro selection and characterization of human immunodefi-ciancy virus Type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J. Vim]. (1998) 72 (9):7532–7541.
- GONG Y, ROBINSON B, ROSE R et al.: Resistance profile and drug combination studies of an 11IV-1 protease inhibitor BMS-232632. Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections Chicago, USA (1999):603.
- O'MARA EM, SMITH J, OLSEN SJ et al: BMS-232632: Single and multiple oral dose safety and pharmacokinetic study in healthy volunteers. Abstracts of the 6th Confer-ence on Retro viruses and Opportunistic Infections Chicago, USA (1999):604.
- LARDER B, BLOUR S, HERTOGS K et al: Tipranavir is active against a large selection of highly protease inhibitor-resistant 111V-1 clinical samples. Antiviral Ther. (1999) 4\(Suppl 1).
- Invirase® (saquinavir mesylate) capsules prescribing information. Nutley, NJ, Roche Laboratories. 1995.
- POZNIAK A, GAZZARD BG, CHURCHILL D eta]. FOR THE BHIVA EXECUTIVE COMMITTEE: British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. http: www. aidsmap .com/bhiva/bhivagd1299.htm. Updated January 7, 2000.
Websites
- ••Consensus report on antiretroviral therapy.